Human Granulocytic Anaplasmosis

Infectious Disease Clinics of North America

Volumn 29, Issue 2, 2015, Pages 341-355

  Bakken, Johan S ^a,b   Dumler, J Stephen ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b St Luke's Infectious Disease Associates   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplasmosis; Diagnosis; Granulocytic; Human; Management

Indexed keywords

DIETHYLTOLUAMIDE; DOXYCYCLINE HYCLATE; ICARIDIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RIFAMPICIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ANAPLASMA PHAGOCYTOPHILUM; ANTIBIOTIC SENSITIVITY; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN GRANULOCYTIC ANAPLASMOSIS; IMMUNE RESPONSE; IXODES PERSULCATUS; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDICAL HISTORY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTECTIVE CLOTHING; REINFECTION; SEROCONVERSION; SEROLOGY; TICK BITE; TREATMENT DURATION; ANAPLASMOSIS; FEVER; GRANULOCYTE; ISOLATION AND PURIFICATION; MICROBIOLOGY; RISK FACTOR;

ANAPLASMA PHAGOCYTOPHILUM; ANAPLASMOSIS; FEVER; GRANULOCYTES; HUMANS; RISK FACTORS;

EID: 84929626540     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.02.007     Document Type: Review

References (81)

1. Ricketts H.T. The study of "Rocky Mountain spotted fever" (tick fever) by means of animal inoculations. JAm Med Assoc 1906, 47:1-10.
2. Pritt BS, McFadden JD, Stromdahl E, etal. Emergence of a novel Ehrlichia sp. agent pathogenic for humans in the Midwestern United States. 6th International Meeting on Rickettsiae and Rickettsial Diseases. Heraklion (Greece): Hellenic Society for Infectious Diseases; 2011. p. 67; Abstract no. P075.
3. Platonov A.E., Karan L.S., Kolyasnikova N.M., et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis 2011, 17:1816-1823.
4. Steere A.C., Malawista S.E., Snydman D.R., et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 1977, 20:7-17.
5. Maeda K., Markowitz N., Hawley R.C., et al. Human infection with Ehrlichia canis, a leukocytic rickettsia. NEngl J Med 1987, 316:853-856.
6. Healy G.R., Speilman A., Gleason N. Human babesiosis: reservoir in infection on Nantucket Island. Science 1976, 192:479-480.
7. Buller R.S., Arens M., Hmiel S.P., et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. NEngl J Med 1999, 341:148-155.
8. Bakken J.S., Dumler J.S., Chen S.M., et al. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging?. JAMA 1994, 272:212-218.
9. Burgdorfer W. Arthropod-borne spirochetoses: a historical perspective. Eur J Clin Microbiol Infect Dis 2001, 20:1-5.
10. McMullan L.K., Folk S.M., Kelly A.J., et al. Anew phlebovirus associated with severe febrile illness in Missouri. NEngl J Med 2012, 367:834-841.
11. Chapman A.S., Bakken J.S., Folk S.M., et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis-United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006, 55:1-27.
12. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1089-1134.
13. Goodman J.L., Nelson C., Vitale B., et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. NEngl J Med 1996, 334:209-215.
14. Bakken J.S., Krueth J., Wilson-Nordskog C., et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996, 275:199-205.
15. Aguero-Rosenfeld M.E., Horowitz H.W., Wormser G.P., et al. Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med 1996, 125:904-908.
16. Horowitz H.W., Aguero-Rosenfeld M.E., McKenna D.F., et al. Clinical and laboratory spectrum of culture-proven human granulocytic ehrlichiosis: comparison with culture-negative cases. Clin Infect Dis 1998, 27:1314-1317.
17. Steere A.C. Lyme disease. NEngl J Med 2001, 345:115-125.
18. Krause P.J. Babesiosis. Med Clin North Am 2002, 86:361-373.
19. Pritt B.S., Sloan L.M., Johnson D.K., et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. NEngl J Med 2011, 365:422-429.
20. McLean D.M., Donohue W.L. Powassan virus: isolation of virus from a fatal case of encephalitis. Can Med Assoc J 1959, 80:708-711.
21. Dahlgren F.S., Mandel E.J., Krebs J.W., et al. Increasing incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007. Am J Trop Med Hyg 2011, 85:124-131.
22. Diuk-Wasser M.A., Hoen A.G., Cislo P., et al. Human risk of infection with Borrelia burgdorferi, the Lyme disease agent, in eastern United States. Am J Trop Med Hyg 2012, 86:320-327.
23. Koffi J.K., Leighton P.A., Pelcat Y., et al. Passive surveillance for I. scapularis ticks: enhanced analysis for early detection of emerging Lyme disease risk. JMed Entomol 2012, 49:400-409.
24. Hao Q., Geng Z., Hou X.X., et al. Seroepidemiological investigation of Lyme disease and human granulocytic anaplasmosis among people living in forest areas of eight provinces in China. Biomed Environ Sci 2013, 26:185-189.
25. Aguero-Rosenfeld M.E., Donnarumma L., Zentmaier L., et al. Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. JClin Microbiol 2002, 40:2612-2615.
26. Bakken J.S., Goellner P., Van Etten M., et al. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin Infect Dis 1998, 27:1491-1496.
27. Belongia E.A., Gale C.M., Reed K.D., et al. Population-based incidence of human granulocytic ehrlichiosis in northwestern Wisconsin, 1997-1999. JInfect Dis 2001, 184:1470-1474.
28. Horowitz H.W., Kilchevsky E., Haber S., et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. NEngl J Med 1998, 339:375-378.
29. Bakken J.S., Krueth J.K., Lund T., et al. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clin Infect Dis 1996, 23:198.
30. Zhang L., Liu Y., Ni D., et al. Nosocomial transmission of human granulocytic anaplasmosis in China. JAMA 2008, 300:2263-2270.
31. Kalantarpour F., Chowdhury I., Wormser G.P., et al. Survival of the human granulocytic ehrlichiosis agent under refrigeration conditions. JClin Microbiol 2000, 38:2398-2399.
32. Leiby D.A., Chung A.P., Cable R.G., et al. Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors. Transfusion 2002, 42:1585-1591.
33. Townsend R.L., Moritz E.D., Fialkow L.B., et al. Probable transfusion-transmission of Anaplasma phagocytophilum by leukoreduced platelets. Transfusion 2014, 54(11):2828-2832.
34. Telford S.R., Dawson J.E., Katavolos P., et al. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc Natl Acad Sci USA 1996, 93:6209-6214.
35. Varde S., Beckley J., Schwartz I. Prevalence of tick-borne pathogens in Ixodes scapularis in a rural New Jersey County. Emerg Infect Dis 1998, 4:97-99.
36. Anderson J.F. The natural history of ticks. Med Clin North Am 2002, 86:205-218.
37. Stafford K.C., Massung R.F., Magnarelli L.A., et al. Infection with agents of human granulocytic ehrlichiosis, Lyme disease, and babesiosis in wild white-footed mice (Peromyscus leucopus) in Connecticut. JClin Microbiol 1999, 37:2887-2892.
38. Mitchell P.D., Reed K.D., Hofkes J.M. Immunoserologic evidence of coinfection with Borrelia burgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. JClin Microbiol 1996, 34:724-727.
39. Dumler J.S., Dotevall L., Gustafson R., et al. Apopulation-based seroepidemiologic study of human granulocytic ehrlichiosis and Lyme borreliosis on the west coast of Sweden. JInfect Dis 1997, 175:720-722.
40. De Martino S.J., Carlyon J.A., Fikrig E. Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis. NEngl J Med 2001, 345:150-151.
41. Bakken J.S., Dumler J.S. Clinical diagnosis and treatment of human granulocytotropic anaplasmosis. Ann N Y Acad Sci 2006, 1078:236-247.
42. Bakken J.S., Dumler J.S. Human granulocytic ehrlichiosis. Clin Infect Dis 2000, 31:554-560.
43. Lee F.S., Chu F.K., Tackley M., et al. Human granulocytic ehrlichiosis presenting as facial diplegia in a 42-year-old woman. Clin Infect Dis 2000, 31:1288-1291.
44. Hardalo C.J., Quagliarello V., Dumler J.S. Human granulocytic ehrlichiosis in Connecticut: report of a fatal case. Clin Infect Dis 1995, 21:910-914.
45. Jahangir A., Kolbert C., Edwards W., et al. Fatal pancarditis associated with human granulocytic ehrlichiosis in a 44-year-old man. Clin Infect Dis 1998, 27:1424-1427.
46. Bakken J.S., Erlemeyer S.A., Kanoff R.J., et al. Demyelinating polyneuropathy associated with human granulocytic ehrlichiosis. Clin Infect Dis 1998, 27:1323-1324.
47. Horowitz H.W., Marks S.J., Weintraub M., et al. Brachial plexopathy associated with human granulocytic ehrlichiosis. Neurology 1996, 46:1026-1029.
48. Lepidi H., Bunnell J.E., Martin M.E., et al. Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg 2000, 62:29-37.
49. Bakken J.S., Aguero-Rosenfeld M.E., Tilden R.L., et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis 2001, 32:862-870.
50. Rand J.V., Tarasen A.J., Kumar J., et al. Intracytoplasmic granulocytic morulae counts on confirmed cases of ehrlichiosis/anaplasmosis in the Northeast. Am J Clin Pathol 2014, 141:683-686.
51. Dumler J.S., Madigan J.E., Pusterla N., et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis 2007, 45(Suppl 1):S45-S51.
52. Massung R.F., Slater K.G. Comparison of PCR assays for detection of the agent of human granulocytic ehrlichiosis, Anaplasma phagocytophilum. JClin Microbiol 2003, 41:717-722.
53. Dumler J.S., Choi K.S., Garcia-Garcia J.C., et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005, 11:1828-1834.
54. Aguero-Rosenfeld M.E. Diagnosis of human granulocytic ehrlichiosis: state of the art. Vector Borne Zoonotic Dis 2002, 2:233-239.
55. Bakken J.S., Haller I., Riddell D., et al. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002, 34:22-27.
56. Belongia E.A., Reed K.D., Mitchell P.D., et al. Tickborne infections as a cause of nonspecific febrile illness in Wisconsin. Clin Infect Dis 2001, 32:1434-1439.
57. Walls J.J., Aguero-Rosenfeld M., Bakken J.S., et al. Inter- and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test. JClin Microbiol 1999, 37:2968-2973.
58. ICD10Data.com. 2014. Available at: Accessed September 19, 2014. http://www.icd10data.com/ICD10CM/Codes/A00-B99/A75-A79/A77-/A77.49.
59. Steere A.C., McHugh G., Damle N., et al. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008, 47:188-195.
60. Wormser G.P., Aguero-Rosenfeld M.E., Cox M.E., et al. Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early Lyme disease. JClin Microbiol 2013, 51:954-958.
61. Horowitz H.W., Hsieh T.C., Aguero-Rosenfeld M.E., et al. Antimicrobial susceptibility of Ehrlichia phagocytophila. Antimicrob Agents Chemother 2001, 45:786-788.
62. Klein M.B., Nelson C.M., Goodman J.L. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother 1997, 41:76-79.
63. Maurin M., Bakken J.S., Dumler J.S. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 2003, 47:413-415.
64. Branger S., Rolain J.M., Raoult D. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis, and Anaplasma phagocytophilum by real-time PCR. Antimicrob Agents Chemother 2004, 48:4822-4828.
65. Bakken J.S., Dumler J.S. Ehrlichia and Anaplasma species. Antimicrobial therapy and vaccine 2002, 875-882. Apple Trees Production, New York. 2nd edition. V. Yu, R. Weber, D. Raoult (Eds.).
66. Committee on Infectious Diseases American Academy of Pediatrics Ehrlichia and Anaplasma infections (human ehrlichiosis and anaplasmosis). Red Book®: 2012 report of the Committee on Infectious Diseases 2012, 312-315. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).
67. Volovitz B., Shkap R., Amir J., et al. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila) 2007, 46:121-126.
68. Buitrago M.I., Ijdo J.W., Rinaudo P., et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis 1998, 27:213-215.
69. Elston D.M. Perinatal transmission of human granulocytic ehrlichiosis. NEngl J Med 1998, 339:1941-1942.
70. Krause P.J., Corrow C.L., Bakken J.S. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. Pediatrics 2003, 112:e252-e253.
71. Wormser G.P., Filozov A., Telford S.R., et al. Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis. Vector Borne Zoonotic Dis 2006, 6:388-394.
72. Belongia E.A., Reed K.D., Mitchell P.D., et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis 1999, 29:1472-1477.
73. Ramsey A.H., Belongia E.A., Gale C.M., et al. Outcomes of treated human granulocytic ehrlichiosis cases. Emerg Infect Dis 2002, 8:398-401.
74. Wallace B.J., Brady G., Ackman D.M., et al. Human granulocytic ehrlichiosis in New York. Arch Intern Med 1998, 158:769-773.
75. Bjoersdorff A., Berglund J., Kristiansen B.E., et al. Varying clinical picture and course of human granulocytic ehrlichiosis. Twelve Scandinavian cases of the new tick-borne zoonosis are presented. Lakartidningen 1999, 96:4200-4204. [in Swedish].
76. Schotthoefer A.M., Meece J.K., Ivacic L.C., et al. Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization. JClin Microbiol 2013, 51:2147-2153.
77. Dumler J.S., Bakken J.S. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. JInfect Dis 1996, 173:1027-1030.
78. Horowitz H.W., Aguero-Rosenfeld M., Dumler J.S., et al. Reinfection with the agent of human granulocytic ehrlichiosis. Ann Intern Med 1998, 129:461-463.
79. Barlough J.E., Madigan J.E., DeRock E., et al. Protection against Ehrlichia equi is conferred by prior infection with the human granulocytotropic Ehrlichia (HGE agent). JClin Microbiol 1995, 33:3333-3334.
80. Sun W., IJdo J.W., Telford S.R., et al. Immunization against the agent of human granulocytic ehrlichiosis in a murine model. JClin Invest 1997, 100:3014-3018.
81. Katavolos P., Armstrong P.M., Dawson J.E., et al. Duration of tick attachment required for transmission of granulocytic ehrlichiosis. JInfect Dis 1998, 177:1422-1425.